Cargando…

Biomimetic Total Synthesis and the Biological Evaluation of Natural Product (−)-Fargesone A as a Novel FXR Agonist

[Image: see text] Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, plays an important role in maintaining or reversing metabolic homeostasis during the development of liver diseases. However, developing FXR modulators to intervene in FXR-related diseases is still an unmet cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Fusheng, Chen, Kaiqi, Dong, Haoran, Hu, Dachao, Gao, Yihui, Liu, Chendi, Laphookhieo, Surat, Lei, Xiaoguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795464/ https://www.ncbi.nlm.nih.gov/pubmed/36590256 http://dx.doi.org/10.1021/jacsau.2c00600

Ejemplares similares

Natural Product 2-Oxokolavenol Is a Novel FXR Agonist
por: Guo, Fusheng, et al.
Publicado: (2022)

C–H Glycosylation of Native Carboxylic Acids: Discovery of Antidiabetic SGLT-2 Inhibitors
por: Wang, Sanshan, et al.
Publicado: (2023)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

Biomimetic Total Synthesis of Enterocin
por: Koser, Lilla, et al.
Publicado: (2021)

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats
por: Wang, Jie-ping, et al.
Publicado: (2022)

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
por: Xi, Lili, et al.
Publicado: (2023)

Synthesis and crystal structure of (±)-Goniotamirenone C
por: Meesakul, Pornphimol, et al.
Publicado: (2020)

FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model
por: Deuschle, Ulrich, et al.
Publicado: (2012)

Update on FXR Biology: Promising Therapeutic Target?
por: Han, Chang Yeob
Publicado: (2018)

Impact of bile acids on the growth of human cholangiocarcinoma via FXR
por: Dai, Jiaqi, et al.
Publicado: (2011)

Biomimetic Approaches to the Synthesis of Natural Disesquiterpenoids: An Update
por: Caprioglio, Diego, et al.
Publicado: (2021)

Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation
por: Schuster, Daniela, et al.
Publicado: (2011)

Alcoholic liver steatosis in mice is aggravated by low-protein diet and reversed by FXR agonist
por: Lívero, Francislaine Aparecida dos Reis, et al.
Publicado: (2012)

Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches
por: Chen, Meimei, et al.
Publicado: (2016)

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid
por: de Haan, Lianne R., et al.
Publicado: (2021)

Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
por: Miyata, Sachiho, et al.
Publicado: (2021)

Novel FXR agonist nelumal A suppresses colitis and inflammation-related colorectal carcinogenesis
por: Miyazaki, Tsuneyuki, et al.
Publicado: (2021)

Stat3 role in the protective effect of FXR Agonist in parenteral nutrition-associated cholestasis
por: Ghosh, Swati, et al.
Publicado: (2023)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer
por: Lu, Lu, et al.
Publicado: (2023)

An extract from date palm fruit (Phoenix dactylifera) acts as a co-agonist ligand for the nuclear receptor FXR and differentially modulates FXR target-gene expression in vitro
por: Alfaro-Viquez, Emilia, et al.
Publicado: (2018)

Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening
por: Diao, Yanyan, et al.
Publicado: (2018)

Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum
por: Grienke, Ulrike, et al.
Publicado: (2011)

Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists
por: Sepe, Valentina, et al.
Publicado: (2016)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

Antimalarial and Cytotoxic Phenolic Compounds from Cratoxylum maingayi and Cratoxylum cochinchinense
por: Laphookhieo, Surat, et al.
Publicado: (2009)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

A Biomimetic Strategy to Access the Silybins: Total Synthesis of (−)-Isosilybin A
por: McDonald, Benjamin R., et al.
Publicado: (2014)

Biomimetically inspired asymmetric total synthesis of (+)-19-dehydroxyl arisandilactone A
por: Han, Yi-Xin, et al.
Publicado: (2017)

Biomimetic Total Synthesis and Investigation of the Non‐Enzymatic Chemistry of Oxazinin A
por: Aniebok, Victor, et al.
Publicado: (2022)

A biomimetic approach for the concise total synthesis of greenwaylactams A–C
por: Kratena, Nicolas, et al.
Publicado: (2023)

Reconstruction of FXR Beam Conditions
por: Nexsen, W E, et al.
Publicado: (2001)

Editorial note: repurposing FDA approved drugs as FXR agonists: a structure based in silico pharmacological study
Publicado: (2022)

Biomimetic and Biological Nanoarchitectonics
por: Ariga, Katsuhiko
Publicado: (2022)

SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR
por: Cui, Shuang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tmii1ms0qhan32v7d92krt4hsr